

CLEAR MICELLIZED FORMULATIONS OF BETA-CAROTENE AND METHOD OF TREATING LEUKOPLAKIA

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention is in the field of formulations of β -carotene, and methods of using such formulations. More particularly, the present invention relates to clear micellized formulations of β -carotene adapted for treating leukoplakia in human patients, and to the process of such treatment.

Brief Description of the Prior Art

β -carotene is a well known naturally occurring substance and has been used in the prior art in nutritional supplements, vitamin or vitamin related formulations, as well as in other formulations applied to the human skin.

United States Patent No. 4,572,915 describes clear, micellized aqueous formulations of several fat soluble vitamins, essential nutrients, herb oils and other fat soluble pharmaceutical agents, including a formulation of β -carotene. The formulations of United States Patent No. 4,572,915 are to be ingested by humans as nutritional and/or vitamin supplements.

Leukoplakia is a disease characterized by formation of white or off-white colored lesions in the mouth which have the potential of developing into oral cancer. It follows that partial or total elimination of the pre-malignant leukoplakia lesions is medically desirable, and may well serve as a life-saving

1 measure by preventing the development of potentially disfiguring or fatal oral
2 cancer. The present invention provides a β -carotene formulation which is
3 specifically adapted for treating leukoplakia lesions with highly favorable
4 results.

5 **SUMMARY OF THE INVENTION**

6 It is an object of the present invention to provide a clear, micellized
7 aqueous formulation of β -carotene in a gel or oral rinse form.

8 It is another object of the present invention to provide a method for
9 treating leukoplakia in human patients.

10 The foregoing and other objects and advantages are attained by a
11 formulation which contains water, β -carotene, a water miscible polyol, an
12 unsaturated fatty acid ester, and a surfactant which is preferably
13 polyethoxylated castor oil, polysorbate or polyethoxyethylene stearate. The
14 formulation preferably also contains a pharmaceutically acceptable anti-
15 oxidant, preferably d-alpha-tocopherol (vitamin E) or its pharmaceutically
16 acceptable derivatives having vitamin E activity. The formulation may be
17 provided as an oral rinse or as a gel well suited for spreading on gums or other
18 parts of the oral cavity.

19 The method of treatment in accordance with the invention comprises
20 applying the formulation of the invention in the gel or oral rinse form on a
21 substantially regular daily basis to areas in the oral cavity where leukoplakia

1 lesions are present. Persistent application of the formulation results in
2 substantial diminution or total elimination of the leukoplakia lesions.

2025 RELEASE UNDER E.O. 14176

DETAILED DESCRIPTION OF THE INVENTION, PREFERRED
EMBODIMENTS AND SPECIFIC EXAMPLES

The following specification sets forth the preferred embodiment of the present invention. The embodiments of the invention disclosed herein are the best modes contemplated by the inventors for carrying out their invention in a commercial environment, although it should be understood that various modifications can be accomplished within the parameters of the present invention.

A principal ingredient in the formulations of the present invention is β -carotene. As is known β -carotene is a naturally occurring product and is considered a precursor to vitamin A. β -carotene is available from several commercial sources, usually as a suspension in an edible or non-toxic oil. The β -carotene which is used in the formulations of the present invention is purchased from a commercial source (Roche). It is itself a formulation containing 30 per cent (%) by weight of β -carotene particles suspended in vegetable oil. The particles of β -carotene in this commercial product are of 10 microns or smaller size. All percentages provided in the present description are on a weight-by-weight basis, unless stated otherwise.

Another important or principal component of the formulations of the present invention is a pharmaceutically acceptable surfactant or emulsifying agent, the preferred example of which is polyethoxylated castor oil.

1 Polyethoxylated castor oil is also available from several commercial sources.
2 The product utilized in the preferred embodiments of the formulations of the
3 present invention is obtained from BASF Aktiengesellschaft, Germany under
4 the tradename CREMOPHOR RH-40 OR CREMOPHOR EL. Polysorbates
5 and polyoxyethylene stearates are examples for other emulsifying agents or
6 surfactants which can be utilized in the formulations and methods of the
7 present invention instead of polyethoxylated castor oil. These other
8 surfactants can also be used in combination with one another and or in
9 combination with polyethoxylated castor oil. A function of the surfactant or
10 emulsifying agent, such as polyethoxylated castor oil of the presently
11 preferred embodiments, is to stabilize in micelles and thereby solubilize the β -
12 carotene. Without micellization β -carotene would be insoluble and could only
13 be suspended as particles in the aqueous medium of the formulation.

14 Still another important or principal component of the formulations of
15 the present invention is a water miscible and pharmaceutically acceptable
16 polyol, the preferred example of which is glycerol. An example for an
17 alternative to glycerol is diethylene glycol. The water miscible,
18 pharmaceutically acceptable polyol acts as an emulsifying or solubilizing
19 agent and also increases the viscosity of the formulations of the invention.
20 The other pharmaceutically acceptable polyol, such as diethylene glycol, can
21 be used in combination with still another acceptable polyol, or in combination

1 with glycerol. Generally speaking, where more than one chemical compound
2 or substance of a certain general category (such as surfactant, polyol,
3 preservative, flavoring agent etc.) can be utilized in the present invention, then
4 instead of a single such compound or substance a combination of substances
5 falling within the same general category can also be used.

6 United States Patent No. 4,572,915, already mentioned above in the
7 introductory section of the present application for patent, describes clear
8 aqueous formulations of fat soluble vitamins and nutritional supplements, and
9 a certain formulation containing β -carotene. To the extent Patent No.
10 4,572,915 discloses information regarding sources for, and/or alternatives of
11 certain components which are utilized in the present invention and also in the
12 products of Patent No. 4,572,915, to that extent the disclosure of Patent No.
13 4,572,915 is useful for the practice of the present invention and is expressly
14 incorporated herein by reference.

15 A further important component of the formulations of the present
16 invention is an ester of an unsaturated fatty acid, the preferred example of
17 which is ethyl linoleate. The ethyl linoleate acts as a solubilizing agent.

18 Another component in the formulations of the present invention is d-
19 alpha-tocopherol (vitamin E) or a pharmaceutically acceptable derivative of d-
20 alpha-tocopherol having vitamin E activity. D-alpha-tocopherol or a
21 derivative having vitamin E activity is not an essential component, but its

1 inclusion is highly advantageous because it serves as a source of vitamin E and
2 also as a natural, pharmaceutically acceptable anti-oxidant. Instead of
3 vitamin E or its derivative, other pharmaceutically acceptable and preferably
4 naturally occurring anti-oxidants can also be used in the formulations of the
5 present invention. Examples for other suitable anti-oxidants are rosemary
6 extract (a natural product), butylated hydroxyanisole (BHA), butylated
7 hydroxytoluene (BHT), and ascorbic acid (vitamin C). Vitamin A palmitate or
8 other pharmaceutically acceptable form of vitamin A is still another optional
9 component of the formulation of the present invention.

10 Still other components or ingredients which are advantageously
11 included in the clear micellized β -carotene formulations of the present
12 invention are described in connection with the description of the two main
13 preferred forms of the formulation, namely a gel adapted for oral
14 administration to leukoplakia affected areas in the oral cavity, and a mouth
15 wash or oral rinse, again adapted for treatment of leukoplakia in the oral
16 cavity. The mouth wash or oral rinse of the present invention can also be
17 utilized as a soothing rinse by persons who are not affected by leukoplakia.

18 **Gel Formulation**

19 Generally speaking, a gel formulation in accordance with the invention
20 contains the following ingredients in the following percentages (weight-by-
21 weight):

ethoxylated castor oil (or equivalent surfactant as described above) 10 to 60 %; deionized or distilled water 10 to 50 %; glycerol (or equivalent polyol, as described above) 5 to 40 %; ethyl linoleate (or equivalent unsaturated fatty acid ester) 1 to 20 %; β -carotene 30 % by-weight suspension in edible oil 0.1 to 30 % by weight, thus containing 0.3 to 9.0 % by weight of actual β -carotene; d-alpha-tocopherol (vitamin E) in a composition containing 1300 IU per gram (or equivalent antioxidant) 0.1 to 12 % by weight, and potassium sorbate 0.1 to 0.5 % by weight.

The potassium sorbate is an optional ingredient and acts as a preservative. Other pharmaceutically acceptable preservatives such as sodium benzoate or paraben can also be used instead of, or in combination with potassium sorbate. Another optional ingredient of the gel is vitamin A palmitate or other pharmaceutically acceptable form of vitamin A.

A more preferred range of the components of the gel formulation of the invention is as follows:

ethoxylated castor oil (or equivalent surfactant as described above) 20 to 40 %;
deionized or distilled water 20 to 40 %;
glycerol (or equivalent polyol, as described above) 10 to 30 %;

1 ethyl linoleate (or equivalent unsaturated fatty acid ester) 1 to 15 %;
2 β -carotene 30 % by-weight suspension in edible oil 1.0 to 10.0 % by
3 weight, thus containing 0.3 to 3.0 % by weight of actual β -carotene;
4 d-alpha-tocopherol (vitamin E) in a composition containing 1300 IU
5 per gram (or equivalent antioxidant) 1 to 5 % by weight, and
6 optionally potassium sorbate 0.1 to 0.5 % by weight.

7 A presently preferred exemplary embodiment of the gel of the present
8 invention has the following composition.

9 ethoxylated castor oil 31 %;
10 deionized water 30 %;
11 glycerol 22 %;
12 ethyl linoleate 8.5 %;
13 β -carotene 30 % by-weight suspension in edible oil 5.60 % by weight,
14 thus containing 1.68 % by weight of actual β -carotene;
15 d-alpha-tocopherol (vitamin E) in a composition containing 1300 IU
16 per gram 2.7 % by weight, and
17 optionally potassium sorbate 0.2 % by weight.

18 Oral Rinse Formulation

19 Again generally speaking, an oral rinse formulation in accordance
20 with the invention contains the following ingredients in the following
21 percentages (weight-by-weight):

1 deionized or distilled water 50 to 95 %;

2 glycerol (or equivalent polyol, as described above) 1 to 10 %;

3 crystalline xylitol, or other sweetener accepted and known in the food

4 and nutritional supplement industry, 1 to 10 %;

5 flavoring agent, such as natural spearmint flavor, in combination of all

6 flavors, 0.2 to 3 %;

7 ethoxylated castor oil (or equivalent surfactant as described above) 0.01

8 to 5 %;

9 sodium benzoate or other preservative 0.01 to 0.5 %;

10 cetyl pyridinium chloride or other pharmaceutically acceptable anti-

11 bacterial agent, 0.01 to 2 %;

12 β-carotene 30 % by-weight suspension in edible oil 0.01 to 4.0 % by

13 weight, thus containing 0.003 to 1.2 % by weight of actual β-carotene;

14 ethyl linoleate (or equivalent unsaturated fatty acid ester) 0.01 to 2 %;

15 disodium EDTA or other pharmaceutically acceptable chelating agent,

16 0.005 to 0.5 %;

17 d-alpha-tocopherol (vitamin E) in a composition containing 1300 IU

18 per gram (or equivalent antioxidant) 0.001 to 2.3 % by weight;

19 vitamin A palmitate in a composition containing 1.7mm IU per gram, or

20 other pharmaceutically acceptable derivative of vitamin A, having vitamin a

21 activity, 0.001 to 1.2 %;

1 a pharmaceutically acceptable anti-foam agent 0.0005 - 0.1 %.

2 Although inclusion of the flavoring agents, sweeteners and chelating
3 agents, such as disodium EDTA, are not essential in the oral rinse formulation
4 of the present invention, these components are advantageous because they help
5 to provide and maintain palatability, non-turbid appearance and a reasonable
6 shelf-life to the oral rinse of the invention. Similarly, the preservatives and
7 antibacterials included in the oral rinse are not absolutely necessary for the
8 oral rinse to function for its intended purposes of acting as a soothing oral
9 rinse and/or treating or preventing development of oral lesions and
10 leukoplakia, but are highly advantageous for providing and maintaining a
11 reasonable shelf-life. The antibacterial agents and the vitamin A in the oral
12 rinse formulation also provide additional benefits to the user, whether the rinse
13 is used to treat or prevent lesions or just as a soothing oral rinse. Examples
14 of anti-bacterial agents other than the cetyl pyridinium chloride if the preferred
15 embodiments are benzalkonium chloride, methylbenzethonium chloride and
16 chlorhexidine gluconate.

17 The anti-foam agent included in the oral rinse composition of the
18 present invention prevents undesired foaming. Such anti-foam agents which
19 are accepted in the pharmaceutical and food- related industry are well known
20 in the art and are available commercially from various sources and usually
21 contain silicone compounds. An example is the well known commercially

1 available "Antifoam A Compound" of Dow Corning, which is itself a
2 formulation and not a single chemical compound.

3 A preferred range of the components of the oral rinse is as follows:
4 deionized or distilled water 70 to 95 %;
5 glycerol (or equivalent polyol, as described above) 2 to 7 %;
6 crystalline xylitol (or other equivalent sweetener) 2 to 7 %;
7 flavoring agent, such as natural spearmint flavor, in combination of all
8 flavors, 0.2 to 1.5 %;
9 ethoxylated castor oil (or equivalent surfactant as described above) 0.01
10 to 1 %;
11 sodium benzoate (or other preservative) 0.01 to 0.5 %;
12 cetyl pyridinium chloride (or other pharmaceutically acceptable anti-
13 bacterial agent) 0.01 to 1 %;
14 β-carotene 30 % by-weight suspension in edible oil 0.01 to 2 % by
15 weight, thus containing 0.003 to 0.60 by weight of actual β-carotene;
16 ethyl linoleate (or equivalent unsaturated fatty acid ester) 0.01 to 0.5 %;
17 disodium EDTA or other pharmaceutically acceptable chelating agent,
18 0.005 to 0.05 %;
19 d-alpha-tocopherol (vitamin E) in a composition containing 1300 IU
20 per gram (or equivalent antioxidant) 0.004 to 0.8 % by weight;
21 vitamin A palmitate in a composition containing 1.7 mm IU per gram,

1 or other pharmaceutically acceptable derivative of vitamin A, having vitamin
2 A activity, 0.001 to 0.3 %;

3 a pharmaceutically acceptable anti-foam agent 0.0005 - 0.01 %.

4 A presently preferred exemplary embodiment of the oral rinse of the
5 present invention has the following composition.

6 deionized water 88.95 %;

7 glycerol 5.1 %;

8 crystalline xylitol 5.0 %;

9 natural spearmint flavor 0.50 %;

10 natural veltol flavor 0.20 %;

11 ethoxylated castor oil 0.090 %;

12 sodium benzoate 0.06 %;

13 cetyl pyridinium chloride 0.0532 %;

14 β-carotene 30 % by-weight suspension in edible oil 0.01867 % by
15 weight, thus containing 0.00560 % by weight of actual β-carotene;

16 ethyl linoleate 0.01500 %;

17 disodium EDTA 0.010 %;

18 d-alpha-tocopherol in a composition containing 1300 IU per gram
19 0.00885 % by weight;

20 vitamin A palmitate in a composition containing 1.7 mm IU per gram
21 0.0055 %;

1 a pharmaceutically acceptable anti-foam agent 0.001 %.

2 Additional ingredients or components such as more or different

3 flavoring agents, sweeteners, coloring agents and additional vitamins (water or

4 fat soluble) may become apparent to those skilled in the art for inclusion both

5 in the gel and oral rinse formulations of the present invention, without

6 departing from the scope and spirit of the invention and without adversely

7 affecting the ability of the formulations to treat leukoplakia. It should also be

8 understood in connection with the herein listed ranges of percentages of the

9 components, that it is not contemplated within the scope of the invention to

10 have all or most of the ingredients present in their respective maximum listed

11 range in any given composition, as such a composition would be incapable of

12 existence for having more than 100 % of the sum of its components. Rather, it

13 is contemplated that when one or more ingredients are in their maximum

14 range, then the ratios of other components are in less than their maximum

15 range, so that the sum total of all components (listed or not listed above) is

16 100 %.

17 **Preparation of the Gel Formulation**

18 It is important for the β -carotene to be solubilized and dispersed in the

19 formulations in a micellized form, because this active ingredient of the

20 aqueous formulations of the invention is absorbed and is substantially

21 effective only when it is micellized. Although the micelle size of β -carotene

1 in the formulations of the present invention has not been actually measured,
2 measurements of somewhat analogous micellized products described in United
3 States Patent No. 4,572,915 indicated that the micelles are of approximately 2
4 microns or smaller. As it is well appreciated by those skilled in the art, clarity
5 of the solution or gel indicates complete micellization whereas turbidity may
6 indicate that the β -carotene is dispersed in particles larger than 2 micron
7 micelles. The ensuing general description discloses a process for preparing
8 or manufacturing the gel formulation of the present invention in such a manner
9 that the result is a clear micellized gel suitable for treating leukoplakia in the
10 manner described below.

11 General Description of the Process of Preparing the Gel Formulation of
12 the Invention:

13 The β -carotene in vegetable oil (30 % active ingredient, obtained from
14 Roche) is mixed with polyethoxylated castor oil and heated under agitation to
15 approximately 160 to 180 °C, and the heating and agitation is continued until
16 a clear homogenous *albeit* colored solution is obtained. Then, while still
17 being agitated the solution is cooled to approximately 130 to 135 °C while d-
18 alpha-tocopherol, glycerol and ethyl linoleate are added. Optionally vitamin
19 A palmitate can also be added in this step. These three or four components
20 themselves are at room or ambient temperature before they are added, and the
21 addition is conducted at such a rate under continuous agitation that the

1 temperature drops to and is maintained, if necessary by heating, at
2 approximately 85 to 90 °C. Agitating in this temperature range is continued
3 until a clear and homogeneous solution is obtained. Thereafter, water, itself
4 heated to approximately 60 °C and optionally potassium sorbate (or other
5 preservative) are added. The mixture is agitated and cooled to ambient
6 temperature until it becomes clear and homogenous to provide the gel
7 formulation of the invention. An example of a specific process is provided
8 below.

9 Specific Example of the Process of Preparing the Gel Formulation of the
10 Invention

11 0.585 kg of polyethoxylated castor oil (CREMOPHOR RH-40 or
12 CREMOPHOR EL, BASF) is mixed with 0.121 kg of β-carotene (30 % actual
13 β-carotene in vegetable oil, Roche) and the mixture is heated to 160 ° to 180 °
14 C and agitated until it becomes clear and homogeneous. Thereafter, the
15 mixture is allowed to cool to 130 °C and 0.057 kg of d-alpha tocopherol
16 composition containing 1300 IU per gram of active ingredient, 0.585 kg of
17 glycerol USP, 0.098 kg of ethyl linoleate and 0.036 kg of vitamin A palmitate
18 (containing 1.7 mm IU per gram, an optional but preferred ingredient) are
19 added while the mixture is agitated and its temperature is allowed to drop to
20 85 to 90 °C, and is maintained under agitation in this temperature range until
21 the mixture is clear and homogeneous. Thereafter, 0.468 kg of deionized

1 water, itself heated to approximately 60 °C, is added under agitation and the
2 mixture is stirred and cooled to ambient temperature until it is clear and
3 homogeneous.

4 **Preparation of the Oral Rinse Formulation**

5 The oral rinse formulation is prepared by mixing the components under
6 continuous agitation at ambient temperature. Advantageously, an aqueous
7 solution of the preservative (sodium benzoate), chelating agent (disodium
8 EDTA) and the antibacterial agent (cetyl pyridinium chloride) is first
9 prepared, the sweetening agent (xylitol) is added , and thereafter the remaining
10 ingredients are added, one-by-one, at ambient temperature. Care is taken that
11 each added component is completely dissolved before the next item is added.

12 **Specific Example of the Process of Preparing the Oral Rinse Formulation
13 of the Invention**

14 519.51 kg of deionized water (137.6 gallons) are added to a vessel
15 equipped with mechanical stirrer. 0.390 kg of sodium benzoate, 0.345 kg of
16 cetyl pyridinium chloride and 0.065 kg of disodium EDTA are added while the
17 mixture is agitated. After each item is completely dissolved 32.47 kg of
18 crystalline xylitol is added, and after it is dissolved the following components
19 are added one after another, each item only after the previously added item has
20 completely dissolved. During this process the mixture is agitated, and is

maintained at ambient temperature:

glycerol USP 32.47 kg;

1.948 kg of the gel prepared in the specific example of the process of making the gel (described above)

natural spearmint flavor 3.247 kg;

natural veltol flavor 1.299kg;

antifoam A compound 0.006 kg;

and more deionized water until a total weight of 649 kg is reached (QS with deionized water to 649 kg).

Methods of Using the Formulations of the Invention

The oral rinse formulation of the present invention is best used by rinsing the mouth with approximately 10 to 15 ml of the liquid rinse for approximately one minute or longer, twice a day or more frequently, as may be recommended by dentist or physician. Besides having a pleasant soothing and anti-bacterial effect, repetitive use frequently diminishes further development of mouth irritation and is expected to forestall or minimize the development of leukoplakia.

The gel formulation of the present invention is to be applied directly to the oral lesion (leukoplakia) preferably *via* a cotton applicator (Q-tip). Typically a dab of the gel sufficient to substantially cover the lesion is used in

1 a single application to a single lesion. Approximately 5 minutes after
2 application the mouth is to be rinsed with warm tap water. The gel is to be
3 applied twice a day to the oral lesion, or more frequently, as recommended by
4 physician.

5 **Clinical Results**

6 An open label clinical trial was carried out on 11 consenting patients
7 with extensive disease consistent with the diagnosis of oral leukoplakia. All
8 patients presented with potentially cancerous pre-malignant lesions, which
9 were bi-dimensionally measurable. A baseline biopsy was taken to rule out the
10 presence of invasive cancer. At the time of enrollment, the patients were not
11 being treated with oral beta-carotene or with retinoids.

12 Characteristics	13 No. of Patients	14 Age(s)
15 Males	16 2	17 72 and 73
18 Females	19 9	20 range 31 - 81 21 (mean 59)

22 The drug used in this study was the clear, transparent micellized gel
formulation of the invention, as specifically described in its preferred
embodiment.

23 Treatment consisted in the topical application of approximately one
24 milliliter of the gel to the oral lesion via a cotton applicator (Q-tip). Five
25 minutes after application, the patient rinsed her/his mouth with warm tap

1 water. Each patient was treated twice daily for three months.

2 Results by the end of the three-month period of treatment were as
3 follows:

	No. of Patients	Observed Effect
5	2	leukoplakia disappeared completely
6	6	leukoplakia decreased by 75 %
7	3	leukoplakia decreased by 50 %

8 In no patient did the lesion fail to decrease by less than 50%.

9 A gel or liquid formulation of the present invention is considered an
10 ideal agent for the treatment of pre-malignant lesions in the oral cavity, since a
11 topical route deposits a high concentration of the effective agent β -carotene at
12 its site of action, while resulting only in minimal degree of systematic
13 absorption. Moreover, the gel and liquid are an ideal vehicle for topical
14 application in the mouth, and because the β -carotene is micellized in the
15 invention, its absorption is greatly increased relative to a non-micellized
16 preparation.